Clinical and genomic features of SPOP-mutant prostate cancer.

Mari Nakazawa Mike Fang Catherine Handy Marshall Tamara L Lotan Pedro Isaacsson Velho Emmanuel S Antonarakis

Published in: The Prostate (2021)

SPOP-mutant prostate cancers represent a unique subset with absent ERG fusions and frequent Wnt pathway alterations, with potentially greater dependency on androgen signaling and enhanced responsiveness to ADT. Outcomes are best for SPOP-altered patients without other concurrent mutations.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
radical prostatectomy
stem cells
peritoneal dialysis
cell proliferation
metabolic syndrome
young adults
insulin resistance
locally advanced
childhood cancer